Rege Nephro
Kyoto
About Rege Nephro
Rege Nephro is a biotech company specializing in R&D, production, and marketing of renal disease therapeutics. It utilizes induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $18.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2024)
- Website: regenephro.co.jp
Industries & Categories
Biotechnology, Manufacturing, Medical, Rental
Social Profiles
Canonical: https://fsome.com/organization/rege-nephro-108889 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.